Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Clinical outcomes of frontline ATG-based immunosuppressive therapy in older patients with aplastic anemia

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJayastu SenapatiSLSanam LoghaviÁBÁlex Bataller

Discussion

Loading...

Member takes

Overview

Analysis shows ATG-based treatment yields 59% response rate in older patients with aplastic anemia, indicating eltrombopag enhances outcomes.

Key Points

  • Frontline ATG-based immunosuppressive therapy achieves a 59% overall response rate among older aplastic anemia patients, revealing its efficacy.
  • Patients ≥70 years exhibited shorter median overall survival and response rates, with 93% showing performance status ≥1.
  • Retrospective analysis of patients aged ≥60 receiving ATG therapy demonstrates significant disease severity impact on long-term outcomes.
  • Eltrombopag addition correlated with improved response rates, suggesting potential in enhancing treatment efficacy for aplastic anemia.

Cite This Study

Senapati et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5c3https://doi.org/10.1182/blood-2025-3206
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Aplastic anemia treatment in older adults in resource-limited settings: Can rabbit ATG bridge the gap?2025
  2. 2Anti-thymocyte globulin-based treatment frequently leads to enduring treatment success in both old and young adult patients with aplastic anaemia: a real-world analysis from the Dutch aplastic anaemia registry2026
  3. 3Thrombopoietin receptor agonists combined with intensive immunosuppressive therapy improve outcomes in elderly patients with severe aplastic anemia: A single-center retrospective study2025
  4. 4Reassessing ASCT in patients aged 65–75 with multiple myeloma in the era of anti-CD38 therapies2025
  5. 5Allograft for myeloid malignancies in the year of 70 years old and beyond: No impact of pre-graft immune, nutritional and inflammatory status on outcome.2025